This inventor holds 1 USPTO granted patent and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignee: Korea Research Institute of Bioscience and Biotechnology. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Van Minh Nguyen: Innovator in Neurodegenerative Disease Treatment
Introduction
Van Minh Nguyen is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurodegenerative diseases. His innovative work focuses on utilizing diterpene-based compounds to address these critical health issues.
Latest Patents
Nguyen holds a patent for a composition aimed at preventing or treating neurodegenerative diseases. This composition comprises a diterpene or a pharmaceutically acceptable salt thereof. The invention specifically targets the inhibition of Nurr1 activity, activating Nurr1 and inhibiting the inflammatory response to combat neurodegenerative diseases.
Career Highlights
Van Minh Nguyen is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His work at this esteemed institution has allowed him to explore and develop groundbreaking solutions in the realm of biotechnology and pharmaceuticals.
Collaborations
Nguyen has collaborated with notable colleagues, including Won Gon Kim and Ha Young Choi. Their combined expertise contributes to the advancement of research in neurodegenerative disease treatments.
Conclusion
Van Minh Nguyen's innovative approach to treating neurodegenerative diseases through his patented compositions highlights his significant role in the field of biotechnology. His contributions continue to pave the way for future advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile